Compounded Semaglutide Providers Compared (2026)

How do compounded semaglutide providers compare on price in 2026?

The July 2026 dataset distinguishes monthly and per-order prices from plans with longer commitments. Cora Health Essential Annual ($99/month, $1,188 billed every 12 months, renews automatically). Cora Health Essential Monthly ($175/month, billed monthly, renews until cancelled).

Monthly or per-order prices from other providers in that edition include Pomegranate Health ($119/month, starting price), Ivim Health ($149.99/month), Trimi Health ($175/month), Mochi Health ($178/month), Eden (TryEden) ($198/month), Belle Health ($199/month), Henry Meds semaglutide injections (checked October 16, 2026) ($297/month), Lemonaid Health ($348/month).

Longer-term examples include Trimi Health annual ($99/month effective, 12-month term) and Belle Health six-month ($119/month effective, six-month term). Check each provider’s site for current prices and terms.

Compounded semaglutide provider comparison (July 2026 dataset)

Competitor prices: Cora Health pricing dataset, July 2026 edition; check each provider's site for current prices. Effective monthly cost includes any required membership or program fees. Starter-dose offers are labelled in the plan name; they do not establish maintenance-dose prices. Compounded medications are not FDA-approved.

Important regulatory note on Belle Health

On February 20, 2026, the US Food and Drug Administration issued a Warning Letter to Belle Health LLC (Draper, Utah) citing violations of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed Belle Health's website in December 2025 and identified that Belle was displaying semaglutide and tirzepatide products with Belle branding in a way that suggested Belle itself manufactured or compounded the medications. Belle Health is a telehealth platform that connects patients with prescribers, not a compounding pharmacy. The letter asked Belle to respond within 15 working days describing the steps taken to address the violations; FDA announced on March 3, 2026 that it had sent 30 such warning letters to telehealth companies. Check FDA's warning-letter database for current status. FDA Warning Letters are publicly searchable in the FDA Warning Letters database.

How compounded semaglutide compares to brand-name Wegovy and Ozempic

Brand-name semaglutide is sold by Novo Nordisk under three trade names — Ozempic for type 2 diabetes (FDA-approved December 2017), Wegovy for chronic weight management (FDA-approved June 2021), and Rybelsus as an oral semaglutide for type 2 diabetes (FDA-approved September 2019). For current brand-name prices and billing conditions, see the GLP-1 cost comparison.

Compounded semaglutide is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Wegovy or Ozempic.

Semaglutide gastrointestinal side effect profile from the STEP 1 trial

Adverse event rates for FDA-approved Wegovy® (semaglutide 2.4 mg) are documented in the STEP 1 trial (Wilding et al., NEJM 2021), the Phase III chronic weight management trial that supported FDA approval of Wegovy. The trial enrolled 1,961 participants randomized 2:1 to weekly semaglutide 2.4 mg (1,306 participants) or placebo (655 participants) over 68 weeks combined with lifestyle intervention.

In the STEP 1 trial of FDA-approved Wegovy® (semaglutide 2.4 mg), mean weight loss was 14.9% over 68 weeks with lifestyle intervention. Individual results vary. These results come from trials of the FDA-approved brand and have not been demonstrated for compounded semaglutide.

Semaglutide 2.4 mg gastrointestinal adverse events (incidence over 68 weeks, semaglutide vs placebo):

• Nausea: 44.2% vs 17.4% placebo
• Diarrhea: 31.5% vs 15.9% placebo
• Vomiting: 24.8% vs 6.6% placebo
• Constipation: 23.4% vs 9.5% placebo
• Treatment discontinuation due to adverse events: 7.0% vs 3.1% placebo
• Serious adverse events: 9.8% vs 6.4% placebo; the difference was mainly due to serious gastrointestinal (1.4% vs 0%) and hepatobiliary (1.3% vs 0.2%) disorders

Most GI events were mild-to-moderate and transient; nausea occurred mainly during dose escalation.

Adverse-event rates from different drugs' trials cannot be directly compared.

Critical compounded semaglutide context. Per the FDA, "compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA — Compounding and the FDA). Adverse event rates for compounded semaglutide have not been formally measured in equivalent trials. Whether a compounded version produces comparable effects depends on formulation, dosing accuracy, and pharmacy quality controls that are not independently verified before marketing — trial-based evidence exists only for the FDA-approved products. Patients evaluating providers should review the full semaglutide and tirzepatide side effects guide for serious warnings — thyroid C-cell tumor boxed warning, pancreatitis, acute kidney injury, gallbladder disease — and individual contraindications before starting treatment. Individual results vary.

What makes a compounded semaglutide provider trustworthy

Beyond price, the substantive trust signals for a compounded semaglutide telehealth provider are pharmacy transparency, accreditation, regulatory standing, and operational maturity.

• Publicly named compounding pharmacy partner — the provider names the specific 503A pharmacy that fills prescriptions on its website rather than referring generically to "licensed pharmacy network"
• PCAB accreditation of the named pharmacy — the Pharmacy Compounding Accreditation Board is an independent audit program for compounding pharmacies (different from FDA approval)
• LegitScript certification of the telehealth platform — required by Google, Meta, payment processors, and other major industry observers
• FDA status — check FDA's warning-letter and compounding-inspection databases for both the platform and the named pharmacy
• USP 797 sterile compounding compliance for injectable preparations
• Use of semaglutide base rather than salt forms (semaglutide sodium or acetate), which FDA describes as different active ingredients from those in approved drugs
• Transparent dose-stable pricing without escalation as the patient titrates from 0.25mg to 2.4mg
• Clear cancellation and refund policy in writing

Provider recommendations by patient profile

The best provider for an individual patient depends on cash budget, plan flexibility preference, and trust signals.

• **Annual billing through Cora Health:** Cora Health Essential Annual ($99/month, $1,188 billed every 12 months, renews automatically). Names US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx.
• **Monthly billing through Cora Health:** Cora Health Essential Monthly ($175/month, billed monthly, renews until cancelled).
• **Annual-term example:** Trimi Health ($99/month effective, 12-month term).
• **Per-order example:** Pomegranate Health ($119/month, starting price in the July 2026 dataset). Pharmacy disclosure: Yes (Hallandale/Empower/OptioRx).
• **One-month-term example:** Mochi Health ($178/month effective in the July 2026 dataset).

Regulatory status of compounded semaglutide in 2026

The compounded semaglutide regulatory landscape continues to evolve. During the FDA-declared semaglutide injection shortage (2022-February 2025), compounding pharmacies had broad authority to prepare copies of Wegovy and Ozempic under the FDA's 503A and 503B exemptions. When the FDA declared the shortage resolved in February 2025, the legal basis for compounding narrowed.

As of May 2026, compounded semaglutide remains legal under specific conditions. A licensed prescriber must write a patient-specific prescription based on a documented clinical need that the commercially available FDA-approved product cannot meet — such as a documented allergy to an inactive ingredient in the commercially available FDA-approved product, a required dose format not available in the branded products, or a documented clinical necessity for a personalized formulation. The compounding pharmacy must be properly licensed (503A or 503B) and must meet applicable quality standards.

On April 30, 2026, the FDA proposed excluding semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list. The public comment period closed June 29, 2026; check FDA's 503B bulks list for current status. The broader regulatory direction is clear: bulk compounding as a substitute for branded Wegovy and Ozempic without documented individual clinical need is increasingly outside the legal exemptions. Patients choosing compounded semaglutide in 2026 should work with providers who stay current on regulatory developments and demonstrate the legal basis for the prescription.

Frequently asked questions about compounded semaglutide providers

Common questions about choosing among compounded semaglutide telehealth options in 2026.

What do compounded semaglutide plans cost by commitment length?

Cora Health Essential Annual ($99/month, $1,188 billed every 12 months, renews automatically). Cora Health Essential Monthly ($175/month, billed monthly, renews until cancelled). In the July 2026 dataset, Trimi Health annual is $99/month effective on a 12-month term; its one-month-term price is $175/month. Other monthly or per-order examples include Pomegranate Health ($119/month, starting price), Ivim Health ($149.99/month) and Henry Meds compounded semaglutide injections ($297/month, checked October 16, 2026). Check each provider’s site for current rates and billing terms.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide is not the same product. Ozempic and Wegovy are FDA-approved finished drugs manufactured by Novo Nordisk under FDA-inspected conditions with validated batch testing. Compounded semaglutide is prepared by a US-licensed compounding pharmacy from semaglutide active pharmaceutical ingredient sourced from FDA-registered suppliers. The finished compounded product is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Ozempic or Wegovy.

Will compounded semaglutide produce the same weight loss as Wegovy?

Clinical trial data for semaglutide for chronic weight management comes from the STEP trial program, which studied only the FDA-approved formulation that became Wegovy. Compounded semaglutide has not been independently trialed. Because compounded semaglutide is not reviewed by the FDA for effectiveness before marketing, there is no independent verification that any given compounded version performs like the trialed product — that depends on formulation, dosing accuracy, and pharmacy quality controls (USP 797 standards govern sterile preparation, not clinical efficacy). Patient-reported experiences are anecdotal and are not a substitute for trial evidence. Individual results vary substantially.

How do I verify a provider's pharmacy partner is legitimate?

Three independent verification steps: (1) Look up the named pharmacy in the state board of pharmacy database for the state where the pharmacy is located — for example, Florida's pharmacy license lookup for Hallandale Pharmacy, or the relevant state for any 503A facility. (2) Check the FDA's public Compounding Inspections and Actions database for any outstanding warning letters or enforcement actions against the named pharmacy. (3) Verify PCAB accreditation status if the provider claims it — PCAB maintains a public directory of currently accredited compounding facilities. Cora Health's partner pharmacies, including Hallandale Pharmacy and VialsRx, are documented at /pharmacy-partners with relevant facility details.

Will my insurance cover compounded semaglutide?

No. Compounded semaglutide is essentially never covered by commercial or government health insurance. Most US health insurance plans cover only FDA-approved finished drug products. Some HSA and FSA accounts allow compounded prescriptions as qualifying medical expenses, but patients should confirm with their HSA/FSA administrator before signing up. Compounded GLP-1 telehealth programs are designed as cash-pay services with payment processed through the provider platform.

Henry Meds program price source

Henry Meds program prices: henrymeds.com/legal/programs (last updated December 3, 2025; checked October 16, 2026).